Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 64

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 64
---
 wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive
programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of
clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a Code of Business Conduct
and Ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we have taken to detect and prevent
this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations
or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted
against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on
our business and results of operations, including the imposition of significant fines or other sanctions.

Unexpected facility shutdowns or system failures may occur and our disaster recovery plans may not be sufficient.

We depend on the performance,
reliability and availability of our properties, machinery, and laboratory equipment and information technology systems. We may not be
able to access our facilities as a result of events beyond our control, such as extreme weather conditions, quarantines, flood, fire,
theft, terrorism and acts of God.

Further, any damage to or
failure of our equipment and/or systems could also result in disruptions to our operations. A complete or partial failure of our information
technology systems, or those of our CROs and other third parties on which we rely, or corruption of data could result in our inability
to access information that we need in order to meet our obligations to our customers or a breach of confidentiality with respect to our
or our customers’ proprietary information. If such an event were to occur and cause interruptions in our operations, it could result
in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed or ongoing clinical
trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.
Our disaster recovery plans may not adequately address every potential event and our insurance policies may not cover any loss in full
or in part (including losses resulting from business interruptions) or damage that we suffer fully or at all. The occurrence of one or
more of these events could have a material adverse effect on our business, financial position, reputation or prospects, and might lead
to a claim for damages.

Our business may be